New inhaled drug could ease breathing for PAH patients

NCT ID NCT07481981

Recruiting now Disease control Sponsor: Insmed Incorporated Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial is testing whether a once-daily inhaled medication called treprostinil palmitil can help adults with pulmonary arterial hypertension (PAH) walk farther. About 344 participants will receive either the drug or a placebo for 24 weeks. The main goal is to see if the drug improves the distance they can walk in six minutes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: treprostinil palmitil inhalation powder
What this could lead to: If successful, this could provide a more convenient once-daily inhaled treatment option to help people with pulmonary arterial hypertension walk farther and manage their condition.
What could go wrong: This is a phase 3 trial, but the drug is still experimental. It may not improve exercise capacity more than placebo, and side effects from the inhaled medication could occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY ARTERIAL HYPERTENSION

Contacts and locations

Locations

USA007
RECRUITING

Anderson, South Carolina, 29621, United States
USA008
RECRUITING

Santa Barbara, California, 93105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.